NasdaqCM - Nasdaq Real Time Price USD

Galectin Therapeutics Inc. (GALT)

Compare
2.3100 +0.2000 (+9.48%)
At close: 4:00:01 PM EST
2.3500 +0.04 (+1.73%)
After hours: 4:33:28 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
39,566.0000
38,072.0000
38,352.0000
30,179.0000
23,444.0000
Operating Income
-39,566.0000
-38,072.0000
-38,352.0000
-30,179.0000
-23,444.0000
Net Non Operating Interest Income Expense
-4,334.0000
-2,562.0000
-981.0000
-486.0000
-21.0000
Other Income Expense
-1,177.0000
-432.0000
557.0000
138.0000
--
Pretax Income
-45,077.0000
-41,066.0000
-38,776.0000
-30,527.0000
-23,465.0000
Net Income Common Stockholders
-45,230.0000
-44,805.0000
-38,873.0000
-30,698.0000
-23,602.0000
Diluted NI Available to Com Stockholders
-45,230.0000
-44,805.0000
-38,873.0000
-30,698.0000
-23,602.0000
Basic EPS
-0.73
-0.74
-0.65
-0.52
-0.41
Diluted EPS
-0.73
-0.74
-0.65
-0.52
-0.41
Basic Average Shares
62,088.7500
60,159.0000
59,391.0000
58,527.0000
57,029.0000
Diluted Average Shares
62,088.7500
60,159.0000
59,391.0000
58,527.0000
57,029.0000
Total Operating Income as Reported
-39,566.0000
-38,072.0000
-38,352.0000
-30,179.0000
-23,444.0000
Total Expenses
39,566.0000
38,072.0000
38,352.0000
30,179.0000
23,444.0000
Net Income from Continuing & Discontinued Operation
-45,077.0000
-41,066.0000
-38,776.0000
-30,527.0000
-23,465.0000
Normalized Income
-43,900.0000
-40,634.0000
-39,333.0000
-30,665.0000
-23,465.0000
Interest Income
328.0000
230.0000
52.0000
3.0000
66.0000
Interest Expense
4,662.0000
2,792.0000
1,033.0000
489.0000
87.0000
Net Interest Income
-4,334.0000
-2,562.0000
-981.0000
-486.0000
-21.0000
EBIT
-40,415.0000
-38,274.0000
-37,743.0000
-30,038.0000
-23,378.0000
EBITDA
-40,379.0000
-38,241.0000
-37,711.0000
-29,997.0000
-23,342.0000
Reconciled Depreciation
36.0000
33.0000
32.0000
41.0000
36.0000
Net Income from Continuing Operation Net Minority Interest
-45,077.0000
-41,066.0000
-38,776.0000
-30,527.0000
-23,465.0000
Total Unusual Items Excluding Goodwill
-1,177.0000
-432.0000
557.0000
138.0000
--
Total Unusual Items
-1,177.0000
-432.0000
557.0000
138.0000
--
Normalized EBITDA
-39,202.0000
-37,809.0000
-38,268.0000
-30,135.0000
-23,342.0000
12/31/2020 - 9/4/2002

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

NMRA Neumora Therapeutics, Inc.
10.87
+5.33%
 
SLS SELLAS Life Sciences Group, Inc.
0.9201
+5.50%
 
ANAB AnaptysBio, Inc.
16.65
+6.80%
 
AVXL Anavex Life Sciences Corp.
9.18
+8.51%
 
CRVS Corvus Pharmaceuticals, Inc.
6.90
-6.50%
 
ALT Altimmune, Inc.
9.00
-0.33%
 
CKPT Checkpoint Therapeutics, Inc.
3.3900
-7.63%
 
VSTM Verastem, Inc.
4.6800
+4.46%
 
HUMA Humacyte, Inc.
4.3400
+5.85%
 
BMEA Biomea Fusion, Inc.
5.85
+3.72%